Positive Early Results Support Continuation of Phase 2 Trial of ATL1102 for DMD
Experimental therapy ATL1102 improved upper limb strength and function in six boys with Duchenne muscular dystrophy (DMD) unable to walk, according to early results of an ongoing Phase 2 clinical trial. These results also indicate that the therapy has been well-tolerated with no safety concerns reported so far.